Following a full submission:
botulinum toxin type A (Botox®) is accepted for use within NHS Scotland.
Indication under review: Management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis, who are not adequately managed with anticholinergics; patients should be already catheterising or willing and able to catheterise if required.
In two phase III, double-blind, placebo-controlled studies, in which all patients received best supportive care, botulinum toxin type A 200 units (licensed dose) was significantly superior to placebo for mean reduction in weekly urinary incontinence episodes, from baseline to week six. There are currently limited data on re-treatment.
Download detailed advice194KB (PDF)
Medicine details
- Medicine name:
- botulinum toxin type a (Botox)
- SMC ID:
- 916/13
- Indication:
- For the management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis, who are not adequately managed with anticholinergics; patients should be already catheterising or willing and able to catheterise if required.
- Pharmaceutical company
- Allergan Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 October 2013